Cervical Cancer
If it’s your first time on this website, please read the disclaimer section.
May 04 – May 11, 2026
Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.
LANCET · Q1 JOURNAL - RANK #1/332TOP-TIER
This global mathematical modelling study used the HPV-ADVISE model to project cervical cancer incidence and inequalities in 67 low-income and 42 high-income countries under various HPV vaccination and screening scenarios. Findings indicate that under current strategies, LMIC incidence would decrease by only 23%, while HICs achieve elimination by 2048, leading to a substantial increase in inequalities (RR=3 in 2022 to 12 in 2105). Reaching 90% girls’ vaccination in LMICs would reduce inequalities (RR=2 in 2105) and achieve elimination outside sub-Saharan Africa. Enhanced prevention strategies, including WHO targets and universal vaccination, are crucial for cervical cancer elimination in LMICs and attenuating global disparities.
10.1016/S0140-6736(26)00410-1
Mar 02 – Mar 09, 2026
Assessing the global demand and supply of brachytherapy resources: a population-based observational study.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This population-based observational study quantified the global demand and supply of brachytherapy resources for six specific cancers, utilizing cancer incidence data from GLOBOCAN 2022 and brachytherapy centre data. It found that 708,948 of 18.5 million new cancer cases in 2022 required brachytherapy, with cervical cancer accounting for 59.3% of indications. Brachytherapy demand was met in 81.5% of HICs but in no LICs, with patients in LICs traveling an average of 551 km compared to 68 km in HICs. These findings highlight profound global inequities in access to this critical cancer treatment, underscoring an urgent need for investment in new centers to improve cancer care worldwide.
10.1016/S1470-2045(25)00718-1